Trinity biotech announces strategic investment in novus diagnostics to advance rapid sepsis testing platform

Dublin, oct. 25, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in novus diagnostics, a company pioneering a rapid sepsis testing platform. this investment will accelerate the development and commercialization of novus' groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infection test.
TRIB Ratings Summary
TRIB Quant Ranking